GlobeNewswire

Zageno and Thomas Scientific to Launch New, Fast and Easy Way to Choose and Purchase the Right Lab Products for Each Specific Experiment at Pittcon, Booth 2423

Dela

Continuously innovating to serve its customers better, century-old Thomas Scientific-the third largest and fastest-growing scientific-equipment company is leveraging startup Zageno, the largest and fastest-growing online marketplace dedicated to the research scientist. Zageno's new platform enables scientists to choose the best products to advance science using a ranking score based on millions of unbiased scientific publications; helps customers procure their products through better integration into their existing processes.

 

ORLANDO, Fla. USA and BERLIN, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., an online biotech marketplace, and Thomas Scientific - a brand-centric, broad-line life-science-equipment, instrument, furniture, consumable, chemical, and laboratory safety supplier with nearly one million high-quality products - announced a U.S. commercial agreement, where Zageno will feature Thomas Scientific's full spectrum of offerings on the Zageno platform. Products are organized logically by process steps and methods (e.g. preparation gene editing; amplification separation: antibodies detection) so research scientists can search and order Thomas's portfolio of products easily, enabling more focus on performing their experiments instead of gathering supplies.

 

Commenting on its latest addition to its life science vendor partner list, Zageno Cofounder and Chief Revenue Officer Florian Wegener, M.D., M.B.A., Ph.D., said, "With its breadth of product offerings from world-leading brands, century-long commitment to serving the research community, and tireless focus on getting things right for customers - Thomas Scientific was a natural vendor partner for Zageno. We're proud to share their booth at Pittcon 2018, where we'll be honored to demonstrate how Zageno can make it easy for Thomas Scientific customers to save time and make better purchasing decisions for their specific scientific studies."

"We're thrilled to enter into this partnership with Zageno," said Thomas Scientific President and Chief Executive Officer Charles Simmons. "Zageno opened up a valuable channel for new customers, allowing us to optimize the focus of our field-based sales force. As an added benefit, Zageno has been able to integrate with our order-intake process, to make our operations more efficient, and make things easy and seamless for the customer."

In creating a biotech-specialized online marketplace, Zageno's founders recognized that scientific product comparison is different than comparing commercial products. Scientists need more information than is readily available on product packaging; nomenclature often varies from manufacturer to manufacturer making it difficult to compare "apples to apples"; and the stakes are high when choosing wrong. Using a non-optimal product in an experiment can lead to flawed data, poor, or non-reproducible results. To help scientists make the best choice possible, Zageno has created a proprietary application algorithm that not only compares specifications, but also incorporates an independent, unbiased "Zageno Scientific Score," based on millions of scientific publications. For the scientist, this simplifies the comparison process, helping her choose the best performing product for her particular experiment, helping to identify and purchase critical products for the work more reliably and driving down time and cost to scientific result.

"With my background in lean six sigma, I'm very conscious of what constitutes value-add time versus non-value-add time, and in biotech research - time spent performing well-designed, reproducible experiments is the ultimate in value-add time," said Zageno Cofounder and Chief Executive Officer David Pumberger, Ph.D. "We have created this marketplace to streamline supply chains and make it as painless and efficient as possible so that all the researcher has to focus on is his or her end point."

About Thomas Scientific ( www.thomassci.com ; twitter:  @ThomasSci )
Thomas Scientific provides the latest in equipment and supplies to the science community. In accordance to the tradition of the original founders, Thomas Scientific itself offers individualized customer service, innovative scientific equipment, and a comprehensive catalog offering a wide selection of product listings at a great deal. We are a registered contractor for the U.S. Federal Government. Thomas Scientific is committed to offering quality laboratory products while catering to the unique needs of the individual customer. For over a century, our dedication to provide the best in science equipment with personal, efficient service sets Thomas apart from the competition. Whether you work in a lab setting or perform your testing in the field, Thomas Scientific has the products you need. We carry everything you need from all of your favorite and trusted suppliers, including Ansell, Avantor(TM) Performance Materials, Becton Dickinson, Buchi, Corning, GE Healthcare, Globe Scientific, Eppendorf, JG Finneran/Porvair, Kimble, Mettler Toledo, Microflex, MilliporeSigma, Thermo Scientific, Wheaton, and more.

About Zageno Inc. ( www.zageno.com ;  twitter:  @ZAGENOteam )
Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions' procurement offices with leading life science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising more than three million products. What do we do? 1) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 2) We make purchasing transactions more efficient for both buyers and sellers. 3) For our vendor partners, we provide a valuable, expanded sales channel. Our growing Zageno team of 50 in Boston, USA, and Berlin, Germany, includes experts in science, e-commerce, systems integration, and customer support to enable smarter, faster processes - allowing more time and resources for value-added science and better research results.

 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/04a8c6dc-312c-4acb-826d-f8926c736be8

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7c42128a-faa4-40d4-aa2e-f662aa0a81dc

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6fb6f0ad-059d-4529-b2c8-a32e70601948

Caroline Grossman for Zageno
Mirepoix LLC
(781) 771-5579
Caroline@mirepoixllc.com

Diane Skala for Thomas Scientific
Thomas Scientific
(856) 832-3296
DianeS@thomassci.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum